

Onyx Dkt No. 1046.ORD USSN: 09/410,462

PATENT

CENTIFICATE OF FIRST CLASS MAILING (37 CFR 1.8)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the following date:

13 NOV 2006

Signature R Fabra

Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE		
In Re Application of: Williams, A., et al.	Confirmation No. 6889	
Serial No.: 09/410,462	Art Unit: 1635	
Filing Date: 1 October 1999	Examiner: J.E. Angell	
Title: A SINGLE AGENT METHOD FOR KI ENDOTHELIAL CELLS USING ADEN	LLING TUMOR AND TUMOR ASSOCIATED	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing are an Information Disclosure Statement, a modified Form PTO-1449, listing seven U.S. Patents and two non-U.S. Patent publications, and copies of the two non-U.S. Patent publications.

Copies of the cited U.S. Patents are not enclosed pursuant the "Changes to Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan," Federal Register, Vol. 69, No. 182.

The Examiner is respectfully requested to make this information of official record in the application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the

11/16/2006 SDENBOB1 00000018 150615 09410462 02 FC:1806 180.00 DA

Onyx Dkt No. 1046.ORD USSN: 09/410,462

PATENT

like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

The Commissioner is hereby authorized to the fee (37 C.F.R. §1.17(p)) for this Information Disclosure Statement (\$180.00) to Deposit Account No. 15-0615 (please reference ONYX1046.ORD). No further fees are believed due. However, the Commissioner is authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 15-0615. This is not authorization to pay the Issue Fee.

Respectfully submitted,

Dated: 3 Nov Zou6

By

Gary R. Fabian


Agent for Applicants Registration No. 33,875

ONYX Pharmaceuticals, Inc. 2100 Powell Street

Emeryville, CA 94608

Phone: (510) 597-6502

Facsimile: (510) 597-6610



Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 1 of 2

In the Application of: Williams, A., et al.

Serial No.: 09/410,462 Filed: 1 October 1999 Confirmation No.: 6889

Art Unit: 1635

Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS

USING ADENOVIRAL MUTANTS

Exam.	Ref.	Document No.	Date	Name	Class	Sub	Filing
Init.	Desig.	Bodument No.	Date	, value	Ciuss	Class	Date
	AD-01	5,677,178	October 14, 1997	McCormick			
	AD-02	5,801,029	September 1, 1998	McCormick			
	AD-03	5,846,945	December 8, 1998	McCormick			<u> </u>
······································	AD-04	5,856,181	January 5, 1999	McCormick			
	AD-05	6,296,845	October 2, 2001	Sampson- Johannes, et al.			
	AD-06	7,001,596	February 21, 2006	Johnson, et al.			
	AD-07	7,078,030	July 18, 2006	Johnson, et al.	1	 	

FOREIGN PATENT DOCUMENTS								
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Coun Paten Office	t Class	Sub Class	Trans YES	lation NO
	BD-01							

Examiner:Date Considered:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ONYX Dkt No.: ONYX1046.ORD

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) Sheet 2 of 2

In the Application of: Williams, A., et al.

Serial No.: 09/410,462 Filed: 1 October 1999 Confirmation No.: 6889

Art Unit: 1635

Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS

USING ADENOVIRAL MUTANTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)				
Exam. Init.	Ref. Desig.	Description		
1, 14	CD-01	Berse, B., et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," Molec. Biol. Cell 1992 Feb;3(2):211-20)		
	CD-02	Warren, R.S., et al., "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis," J. Clin. Invest. 1995 Apr;95(4):1789-97		

Examiner:	Date Considered:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.